01 · Equity deep-dive — synthesized analyst desk
LLY
$1,306.69 ▲ at the 52-wk high
NYSE · PHARMA / METABOLICMKT CAP ≈ $1.17T52-WK $806.02 – $1,321.21AS OF OCT 22, 2026 CLOSE

The business is running at maximum dose. The stock may already price the full response.

Revenue is up 48% and guidance has been raised twice, yet the shares sit at an all-time high only ~1% below the Street’s mean target. The Q3 print lands Oct 29. The question: does volume keep outrunning falling net price?

The verdict · TL;DR
One question decides the stock: is falling net price a rounding error against volume, or the start of a margin peak? Fundamentals are exceptional; valuation (~33x forward, ~30% over Morningstar fair value) leaves little cushion. Great company, demanding price, wide outcome range.
5-yr · prob-weighted
$1,564
+20% vs $1,306.69
52-week playback · where the tape sits❚❚ At the highs
$1,306.69 · Oct 22, 2026consensus $1,317 · +1%
$806.02 · 52-wk low · late Oct ’25$1,321.21 · 52-wk high · Oct 22 ’26
Price history + cone of outcomes · Oct 2025 → mid-2031
HISTORICALBULLBASEBEARPROB-WTDSTREET 12-MO
$400$800$1,200$1,600$2,000$2,400$2,800Nov '25Jan '26MarMayJulSepmid-'27mid-'28mid-'29mid-'31 $806 · 52-wk low · late Oct ’25 $1,134 · Jan ’26 high $1,321 ATH · Oct 22 ’26 $1,564 $1,334$1,404$1,495 $2,660$1,572$640 TODAY · $1,306.69

Gray = LLY price through Oct 22, 2026, a 12-month window drawn from dated closes and disclosures (straight segments between anchors, not daily data); colored paths = scenario midpoints, probability-weighted (bear 30% · base 45% · bull 25%). Bear-tilted because the stock is at a record, trades ~30% above Morningstar fair value, and sits at the Street mean target. Open circle = Street mean ~$1,317. Scenarios are illustrative frameworks, not forecasts.

Re-weight the scenarios

Make the odds yours. Drag to set bear and bull (base takes the remainder); the blended target, the dotted line on the chart, and the prob-weighted rows below update live.

30% bear45% base25% bull
Blended 5-yr expected$1,564+20% vs $1,306.69
+48%
Q2’26 revenue ($22.97B)
+91%
Mounjaro ($9.9B)
+44%
Zepbound ($4.9B)
$8.38
Non-GAAP EPS, +33% (incl. $3.03 IPR&D)
$18.2B
TTM free cash flow
$85–87B
FY26 revenue guide (raised)
$35.50–36.50
FY26 non-GAAP EPS guide
$98M
Foundayo (oral GLP-1) Q2 sales
02 · The panel — six ways to read one dose-response curve

Six analyst lenses, six answers

Synthesized perspectives with their own 12-month targets (panel mean ~$1,192 vs Street ~$1,317). Not real people or real firm ratings.

Growth / Momentum PM

The Volume Compounder

Revenue +48% at $80B TTM, Mounjaro +91%, ex-US +80% on China NRDL, retatrutide filing Q1 2027. Earnings still compounding 20%+ through 2028.

12-MO TARGET $1,500 · ~32x NTM EPS ~$47 · conviction High
Value / FCF Analyst

The Cash Counter

TTM FCF $18.2B is only a ~1.6% yield on a $1.17T cap, debt is $54.9B and capex is $9.9B and rising. Quality is superb; the price already pays for it.

12-MO TARGET $1,020 · ~22x NTM EPS ~$46 · conviction Medium
Disruption Skeptic

The Price-Taker Thesis

Net price is falling (US price −3% even after rebate true-ups), Medicare and cash-pay channels reset the base, and Novo’s oral Wegovy led Foundayo to market.

12-MO TARGET $850 · ~20x NTM EPS ~$42 · conviction Medium
Moat / Strategy Analyst

The Capacity Moat

Ten new US sites since 2020 and a $5B Virginia plant: manufacturing scale and the dual-incretin franchise are the barrier. Share of GLP-1 market was 58% in Q3 2025.

12-MO TARGET $1,380 · ~30x NTM EPS ~$46 · conviction High
Quant / Technical

The Breakout

Record high Oct 20 on a 97% 52-wk range position; forward P/E ~33x vs a 5-yr average ~40x. Momentum favors holders, but RSI-type overbought risk into Oct 29.

12-MO TARGET $1,300 · ~28x NTM EPS ~$46 · conviction Low
Macro / Policy Strategist

The Policy Meter

Medicare GLP-1 Bridge started July, tariff grace tied to price deals, China export threats in the news. Sector rotation into defensives is a tailwind that can reverse.

12-MO TARGET $1,100 · ~24x NTM EPS ~$46 · conviction Medium
03 · Wall Street’s read

Wall Street 12-month price targets

Sorted low to high; dashed line is today’s $1,306.69. Most recent targets sit within ~10% of the price.

Mean ≈ $1,317 (+1%) · range $891–$1,600 · selected firms, date of last seen target
BUYHOLDSELL
HSBC (Mar ’26)$850Redburn (Apr ’26)$880Berenberg (Feb ’26)$1,050Wells Fargo (Feb ’26)$1,280Leerink (Oct 21)$1,316Bernstein (Jul 14)$1,385Goldman Sachs (Oct 20)$1,413UBS (Jul 13)$1,425Morgan Stanley (Oct 7)$1,430Cantor (Oct 8)$1,440TODAY · $1,306.69

Consensus per TradingKey (Oct 22, 2026): mean $1,316.96, high $1,600, low $891.22; Yahoo shows a $1,331.55 one-year estimate; MarketBeat counts 1 Strong Buy, 24 Buy, 3 Hold, 1 Sell. HSBC, Redburn and Berenberg targets are older (dates shown) and may have changed.

04 · Price scenarios — 1 / 2 / 3 / 5 years

Where the dose-response leads

Scenario price = EPS × exit multiple. Returns vs. $1,306.69. Illustrative frameworks, not forecasts.

1 Year

Mid-2027
Bull$1,716+31%
Base$1,334+2%
Bear$800−39%
Prob-wtd$1,269−3%

2 Years

Mid-2028
Bull$2,048+57%
Base$1,404+7%
Bear$684−48%
Prob-wtd$1,349+3%

3 Years

Mid-2029
Bull$2,280+74%
Base$1,495+14%
Bear$646−51%
Prob-wtd$1,437+10%

5 Years

Mid-2031
Bull$2,660+104%
Base$1,572+20%
Bear$640−51%
Prob-wtd$1,564+20%
▸ Bull case — show the assumptions & math
Retatrutide files in Q1 2027 and launches on schedule, Foundayo scales internationally, tirzepatide ex-US keeps compounding, volume outruns net-price erosion and operating leverage holds near 50%.
1–3 yr: NTM EPS $52 / $64 / $76 × 33 / 32 / 30× · 5 yr: 2031E EPS ~$95 × 28× → $2,660
▸ Base case — show the assumptions & math
Revenue passes $98B in 2027 (consensus ~$99B) and EPS compounds ~22% then ~10% a year per consensus growth rates; net price erodes but volume covers it; the multiple drifts from ~33x forward toward the low-to-mid 20s.
1–3 yr: NTM EPS $46 / $52 / $57.5 × 29 / 27 / 26× · 5 yr: 2031E EPS $65.5 × 24× → $1,572
▸ Bear case — show the assumptions & math
Medicare and direct-to-consumer pricing resets, oral competition and payer step-edits compress net price faster than volume grows; EPS stalls near today’s run-rate and the multiple falls to a mature-large-pharma level.
1–3 yr: NTM EPS $40 / $38 / $38 × 20 / 18 / 17× · 5 yr: EPS ~$40 × 16× → $640
05 · Follow the cash

Revenue, capex, free cash flow & debt ($B)

Cash generation has exploded, but so has the capital it takes to make the drug.

Annual revenue, capex, FCF & total debt · 2023 → TTM Jun ’26
REVENUECAPEXFREE CASH FLOWTOTAL DEBT
$0$25$50$75$100202320242025TTM Jun ’26

Revenue $34.1B / $45.0B / $65.2B / $79.7B TTM; capex $3.4B / $5.1B / $7.8B / $9.9B; FCF $0.8B / $3.8B / $9.0B / $18.2B; debt $25.2B / $33.6B / $42.5B (10-K) and $54.9B at Jun ’26 (aggregator, includes leases). The bull sees FCF compounding; the bear sees capex and debt climbing with it.

06 · Earnings power

EPS path underpinning the targets ($)

Each target is an EPS estimate times an exit multiple. This is the ladder.

Adjusted EPS · reported vs. estimated, 2024 → 2031E
REPORTEDESTIMATE
$0$20$40$60$80$12.982024$24.212025$36.002026E$43.502027E$49.102028E$54.502029E$60.202030E$65.502031E

Reported non-GAAP: $24.21 (2025, per Lilly) and ~$12.98 (2024). 2026E = guidance midpoint $36.00 (includes $3.03 Q2 IPR&D). 2027E ~$43.50 and 2028E ~$49.10 follow consensus (FY27 earnings ~$38.4B, 2028 average $49.14); 2029–31E extend at consensus growth rates (+11%, +10%, +9%). Base 2031E EPS $65.5 × 24x ≈ $1,572.

07 · Growth scorecard

The business is still growing

Q2 FY26, year-over-year — read these against a stock at its record.

Year-over-year growth by metric · Q2 FY26
COREFRONTIER
Reported EPS+26%US revenue+33%Non-GAAP EPS+33%Zepbound+44%Total revenue+48%Ex-US revenue+80%Mounjaro+91%

Unlike a beaten-down name, the disconnect here runs the other way: growth is intact and the stock has re-rated to a record, so the bull no longer has a valuation cushion. Zepbound growth shown per Lilly’s release (44%); some outlets print 46%.

08 · The debate

Bull vs. Bear

Core debate: volume growth versus a shrinking net price on the same molecule.

▲ THE BULL CASE

  • Growth is not slowing. Q2 revenue +48% to $22.97B vs $20.82B expected; FY26 guide raised twice to $85–87B (Aug 5).
  • Profit outruns sales. Non-GAAP EPS +33% despite $3.03 of IPR&D; TTM operating margin 49.7% vs 42.1% a year earlier.
  • Pipeline depth. Retatrutide has a complete obesity data package with an FDA filing planned Q1 2027; Foundayo cleared the EMA committee Oct 15.
  • Global leg is just starting. Ex-US revenue +80% with Mounjaro on China’s NRDL; Mounjaro international +172%.
  • Capacity is the moat. $5B Virginia groundbreaking (Oct 22), $4.5B more in Indiana, 10 new US sites since 2020.
  • Estimates still rising. Goldman ($1,413), Morgan Stanley ($1,430) and Cantor ($1,440) all lifted targets in October ahead of the Oct 29 print.

▼ THE BEAR CASE

  • Priced for perfection. 43.9x trailing and ~33x forward earnings; Morningstar fair value ~$980, a ~30% premium; Street mean target ($1,317) is only ~1% above the price.
  • Net price is shrinking. US Q2 price −3%, and about −9% without rebate true-ups; Medicare GLP-1 Bridge began in July.
  • Oral race is not won. Foundayo did $98M in Q2 vs about $500M for Novo’s Wegovy pill, which launched first.
  • Capital intensity climbing. TTM capex $9.9B (vs $3.4B in 2023); total debt $54.9B incl. leases vs $25.2B in 2023.
  • Earnings are noisy. Big BD deals: $3.03 per share of acquired IPR&D hit Q2; more deals are likely.
  • Concentration. Mounjaro + Zepbound are ~$14.8B of $22.97B in Q2; a safety, policy or supply shock hits most of the company at once.
09 · Risk map

Risk map — likelihood × impact

The hot corner — likely and high-impact — is net-price erosion; the genuine tail is a class-wide safety shock.

Low impact
Medium impact
High impact
Likely
  • IPR&D noise
  • Multiple de-rating
  • Capex & leverage
  • Net-price erosion
Possible
  • Oral launch
  • Retatrutide setback
Tail
  • China / trade
  • Class safety shock

Net-price erosion

Likely × High

Medicare, cash-pay and payer pressure cut net price faster than volume grows, compressing revenue per script and margin.

Multiple de-rating

Likely × Medium

At ~33x forward the stock sits on growth durability; a growth wobble resets the multiple toward 25x.

Capex & leverage creep

Likely × Medium

Capex and debt keep climbing, trimming free cash flow conversion and the buyback capacity.

IPR&D noise

Likely × Low

Business-development charges swing quarterly EPS and can mask the underlying beat.

Oral launch shortfall

Possible × Medium

Foundayo fails to scale against Novo’s earlier oral Wegovy, leaving the oral TAM to the competitor.

Retatrutide setback

Possible × High

A safety or label surprise delays the Q1 2027 filing and the next growth leg.

Class safety shock

Tail × High

A GLP-1 class safety finding or regulatory action reprices the whole franchise.

China / trade shock

Tail × Medium

Export threats or tariffs hit the fastest-growing ex-US line.

10 · Plain-language glossary

The jargon, decoded

Hover the dotted terms in the metrics, or scan the working definitions.

Net price / gross-to-net
Revenue per prescription after rebates and discounts; falling net price is the bear’s core worry.
GLP-1 / incretin
Drug class that mimics gut hormones to cut appetite and blood sugar; Mounjaro and Zepbound are dual GIP/GLP-1.
Acquired IPR&D
Up-front cost of buying unfinished drug assets, expensed at once ($3.03/share in Q2’26).
Non-GAAP EPS
Earnings per share excluding items management treats as non-core; Lilly still includes IPR&D.
Free cash flow
Operating cash flow minus capex; ~$18.2B TTM, a ~1.6% yield at today’s market cap.
Forward P/E
Price divided by next-12-month earnings estimate; ~33x vs a ~40x five-year average.
Exit multiple
P/E assumed at the forecast end; times EPS gives the scenario price.
Prob-weighted
Each scenario price times its probability, summed into one expected value.